Research programme: monoclonal antibodies - Scotia
Alternative Names: SC 104 - ScotiaLatest Information Update: 17 Jul 2001
Price :
$50 *
At a glance
- Originator Scotia Pharmaceuticals [CEASED]
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Radiation injuries
Most Recent Events
- 17 Jul 2001 Discontinued-Preclinical for Radiation injuries (Prevention)/Radioprotection in United Kingdom (Unknown route)
- 21 Mar 1997 Preclinical development for Radiation injuries (Prevention)/Radioprotection in United Kingdom (Unknown route)